StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio total assets

Total assets on the balance sheet at the end of each period.

Inmune Bio's total assets was $26.85M at Jun 30, 2026. For fiscal 2025 it was $32.35M, down 18.2% from the year before. The highest annual figure on record is $99.95M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.35M-18.2%
FY2024Dec 31, 2024$39.56M-30.6%
FY2023Dec 31, 2023$57.00M-30.3%
FY2022Dec 31, 2022$81.80M-18.2%
FY2021Dec 31, 2021$99.95M+145.8%
FY2020Dec 31, 2020$40.66M+66.1%
FY2019Dec 31, 2019$24.47M+40.9%
FY2018Dec 31, 2018$17.36M-5.7%
FY2017Dec 31, 2017$18.41M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$26.85M-28.8%
Q1 FY2026Mar 31, 2026$25.82M-31.7%
Q4 FY2025Dec 31, 2025$32.35M-18.2%
Q3 FY2025Sep 30, 2025$33.36M-36.8%
Q2 FY2025Jun 30, 2025$37.68M-28.2%
Q1 FY2025Mar 31, 2025$37.80M-19.3%
Q4 FY2024Dec 31, 2024$39.56M-30.6%
Q3 FY2024Sep 30, 2024$52.78M-15.8%
Q2 FY2024Jun 30, 2024$52.45M-24.8%
Q1 FY2024Mar 31, 2024$46.83M-36.7%
Q4 FY2023Dec 31, 2023$57.00M-30.3%
Q3 FY2023Sep 30, 2023$62.70M-25.2%
Q2 FY2023Jun 30, 2023$69.72M-20.6%
Q1 FY2023Mar 31, 2023$73.98M-21.6%
Q4 FY2022Dec 31, 2022$81.80M-18.2%
Q3 FY2022Sep 30, 2022$83.80M-22.2%
Q2 FY2022Jun 30, 2022$87.81M+44.7%
Q1 FY2022Mar 31, 2022$94.35M+43.2%
Q4 FY2021Dec 31, 2021$99.95M+145.8%
Q3 FY2021Sep 30, 2021$107.67M+151.5%
Q2 FY2021Jun 30, 2021$60.70M+163.4%
Q1 FY2021Mar 31, 2021$65.87M+178.2%
Q4 FY2020Dec 31, 2020$40.66M+66.1%
Q3 FY2020Sep 30, 2020$42.82M+68.6%
Q2 FY2020Jun 30, 2020$23.05M-16.3%
Q1 FY2020Mar 31, 2020$23.68M+0.1%
Q4 FY2019Dec 31, 2019$24.47M+40.9%
Q3 FY2019Sep 30, 2019$25.40M+37.9%
Q2 FY2019Jun 30, 2019$27.53M–
Q1 FY2019Mar 31, 2019$23.64M–
Q4 FY2018Dec 31, 2018$17.36M–
Q4 FY2017Dec 31, 2017$18.41M–

More Inmune Bio figures

See a number that looks wrong?